These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 11075938

  • 1. Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.
    Jørgensen LB, Katzenstein TL, Gerstoft J, Mathiesen LR, Pedersen C, Nielsen C.
    Antivir Ther; 2000 Sep; 5(3):187-94. PubMed ID: 11075938
    [Abstract] [Full Text] [Related]

  • 2. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjaer J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L, EuroSIDA Study Group.
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S, Yeni PG, Bouchaud O, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV.
    Clin Infect Dis; 2007 Jan 01; 44(1):120-7. PubMed ID: 17143827
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM, Bonjoch A, Iribarren J, Galindo MJ, Negredo E, Domingo P, Pérez-Alvarez N, Martinez-Picado J, Schapiro J, Clotet B, HIV Conference Call Study Group.
    HIV Med; 2008 Aug 01; 9(7):508-13. PubMed ID: 18484978
    [Abstract] [Full Text] [Related]

  • 7. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
    Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA.
    J Infect Dis; 1999 Jun 01; 179(6):1375-81. PubMed ID: 10228057
    [Abstract] [Full Text] [Related]

  • 8. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C, Peytavin G, Dominguez S, Marcelin AG, Duvivier C, Gourlain K, Amellal B, Legrand M, Raffi F, Costagliola D, Katlama C, Calvez V.
    J Med Virol; 2005 Nov 01; 77(3):345-50. PubMed ID: 16173015
    [Abstract] [Full Text] [Related]

  • 9. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
    Røge BT, Katzenstein TL, Obel N, Nielsen H, Kirk O, Pedersen C, Mathiesen L, Lundgren J, Gerstoft J.
    Antivir Ther; 2003 Apr 01; 8(2):173-82. PubMed ID: 12741630
    [Abstract] [Full Text] [Related]

  • 10. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Harrigan PR, Hertogs K, Verbiest W, Larder B, Yip B, Brumme ZL, Alexander C, Tilley J, O'Shaughnessy MV, Montaner JS.
    Antivir Ther; 2003 Oct 01; 8(5):395-402. PubMed ID: 14640386
    [Abstract] [Full Text] [Related]

  • 11. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M, Staszewski S, Doerr HW.
    Antivir Ther; 2007 Oct 01; 12(5):695-703. PubMed ID: 17713153
    [Abstract] [Full Text] [Related]

  • 12. Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.
    Maggiolo F, Callegaro A, Arici C, Quinzan G, Gregis G, Ripamonti D, Tebaldi A, Goglio A, Suter F.
    Antivir Ther; 2003 Apr 01; 8(2):121-6. PubMed ID: 12741624
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
    Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM, Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team.
    N Engl J Med; 2003 Sep 11; 349(11):1036-46. PubMed ID: 12968087
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P.
    J Infect Dis; 2001 Jun 15; 183(12):1732-8. PubMed ID: 11372025
    [Abstract] [Full Text] [Related]

  • 20. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.
    Clin Infect Dis; 2007 Feb 01; 44(3):447-52. PubMed ID: 17205457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.